Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Enfamil Growth Paces Strong Nutritionals Performance For Bristol-Myers

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb's Enfamil infant formula brand posted sales growth of 24% to $175 mil. in the fourth quarter, contributing to a continued strong showing by the company's nutritional business. Quarterly sales in the U.S. increased 19% to $150 mil. For the year, Enfamil sales were up 13%, totaling $621 mil. worldwide, while U.S. sales rose 10% to $560 mil.

You may also be interested in...

Excedrin Migraine Full Migraine Indication Approved By FDA

Bristol-Myers Squibb's Excedrin Migraine indication for full migraine syndrome was approved by FDA Oct. 7. The new labeling simply bears the indication "Treats migraine."

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts